Comparison of CL Wear Between Two Allergy Drops
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00489398 |
Recruitment Status :
Withdrawn
(Protocol changes)
First Posted : June 21, 2007
Last Update Posted : October 7, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Allergic Conjunctivitis | Drug: epinastine HCL and olopatadine HCL | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 25 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single |
Primary Purpose: | Treatment |
Official Title: | Comparison of CL Wear Between Epinastine Hydrochloride and Olopatadine Hydrochloride |
Study Start Date : | July 2007 |
Estimated Study Completion Date : | December 2008 |

- Contact lens objective and subjective clinical performance testing [ Time Frame: up to 3 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Males or females > 18 years old
- Mild to moderate dry eye symptoms
- Likely to complete all study visits and able to provide informed consent
Exclusion Criteria:
- Current use of topical cyclosporine
- Known contraindications to any study medication or ingredients
- Active ocular diseases or uncontrolled systemic disease (blepharitis patients that are actively being treated or disease that is uncontrollable)
- Ocular surgery within the past 3 months

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00489398
Study Director: | Milton M Hom, OD FAAO | Private Practice |
Responsible Party: | Milton M. Hom, OD, FAAO. |
ClinicalTrials.gov Identifier: | NCT00489398 |
Other Study ID Numbers: |
5316 |
First Posted: | June 21, 2007 Key Record Dates |
Last Update Posted: | October 7, 2010 |
Last Verified: | October 2010 |
Conjunctivitis Conjunctivitis, Allergic Conjunctival Diseases Eye Diseases Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Olopatadine Hydrochloride Epinastine Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics |
Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Anti-Allergic Agents Histamine H1 Antagonists, Non-Sedating Histamine H1 Antagonists Histamine Antagonists Histamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |